The startup's technology uses a droplet microfluidics approach for cell isolation and phenotypic detection, and is being targeted for use by hospitals.
Inspired by the electronic breadboards used to prototype electronic devices, the system is meant to enable flexible and inexpensive design of clinical tests.
According to project organizers, feasibility testing in the first phase of the project was successful and clinical trials are planned for later this year.
The test would also be used to detect antibiotic susceptibility. Fraunhofer received £900,000 from SBRI Healthcare in support of the project to develop the test.
According to CEO Eugene Chan, the CE designation is just the first of more to come, as the company enters the diagnostics market with a focus on hematological testing.
Given the high yield of miRNA markers they were able to isolate, the researchers believe the approach could be commercialized for routine cancer testing.
